



# SPAFID CONNECT

Informazione Regolamentata n. 0472-6-2018	Data/Ora Ricezione 16 Febbraio 2018 09:35:28	MTA - Star
---	--	------------

Societa' : BB BIOTECH

Identificativo : 99139

Informazione  
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : 1.1

Data/Ora Ricezione : 16 Febbraio 2018 09:35:28

Data/Ora Inizio : 16 Febbraio 2018 09:35:29

Diffusione presunta

Oggetto : Annual report of BB Biotech AG as of  
December 31, 2017

*Testo del comunicato*

Vedi allegato.

Media release as of February 16, 2018

Annual report of BB Biotech AG as of December 31, 2017

## **BB Biotech AG publishes its 2017 annual report**

BB Biotech AG published its annual report for fiscal year 2017 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech's positioning, the therapeutic areas covered by its portfolio and the companies it is invested in.

For 2017, BB Biotech's total share return of 23.1% in CHF and 13.1% in EUR was built on the strong portfolio performance. Strengthening of the EUR over the USD was a major headwind for EUR denominated performance. The portfolio Net Asset Value (NAV) increased by 23.4% in CHF, 12.5% in EUR and 29.2% in USD in the same period, outperforming its benchmark Nasdaq Biotechnology Index by 7.5%. Consolidated and audited full year 2017 data showed a net gain of CHF 688 mn compared to a net loss of CHF 802 mn in the previous period.

As already announced on January 19, 2018, BB Biotech will propose an ordinary dividend of CHF 3.30 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2017. This marks a continuation of the dividend policy as introduced in 2013.

BB Biotech's annual report 2017 can be downloaded at [www.bbbiotech.com](http://www.bbbiotech.com).

### **For further information:**

#### **Investor Relations**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00  
Dr. Silvia Schanz, [ssc@bellevue.ch](mailto:ssc@bellevue.ch)  
Maria-Grazia Iten-Alderuccio, [mga@bellevue.ch](mailto:mga@bellevue.ch)  
Claude Mikkelsen, [cmi@bellevue.ch](mailto:cmi@bellevue.ch)

#### **Media Relations**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00  
Tanja Chicherio, [tch@bellevue.ch](mailto:tch@bellevue.ch)

TE Communications AG, Bleichstrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28  
Thomas Egger, [teg@te-communications.ch](mailto:teg@te-communications.ch)

### **[www.bbbiotech.com](http://www.bbbiotech.com)**

#### **Company profile**

BB Biotech invests in companies in the fast-growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

#### **Disclaimer**

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Fine Comunicato n.0472-6

Numero di Pagine: 3